Tactile Medical Appoints Peter Schaubach as Chief Information Officer

MINNEAPOLIS, March 19, 2019 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced the appointment of Peter Schaubach to the position of Chief Information Officer (CIO), effective January 21, 2019.

“Peter is a welcome addition to our leadership team and possesses a strong background in helping companies in the medical technology industry grow,” said Gerald R. Mattys, Chief Executive Officer of Tactile Medical. “He is focused initially on preparing Tactile Medical as we move to our new corporate facility and leading our process improvement initiatives to better serve our patient, clinician and payer customers.”

Mr. Schaubach joins Tactile Medical with more than 20 years of experience in information technology, including significant leadership experience at public companies in the medical device industry. Mr. Schaubach was previously the Chief Information Officer at K2M Group Holdings, Inc. (“K2M”), a global medical device company, from 2013 until the company’s acquisition by Stryker Corporation in 2018. As a member of K2M’s executive leadership team, Mr. Schaubach developed the company’s global IT organization and coordinated the company’s transition to its new corporate headquarters in Leesburg, VA and a new facility in London. Prior to joining K2M, he served as a Principal Consultant on the Life Sciences team at QAD, Inc., a developer of enterprise systems software for global manufacturing companies, from 2011 until 2013.

From 2008 until 2010, Mr. Schaubach was the Chief Information Officer at AGA Medical, a global medical device company, where he managed the implementation of the company’s IT infrastructure and systems, assisting in the establishment of its direct sales and distribution infrastructure in Europe. He also served as Chief Information Officer at ev3 Inc., a global medical device company, from 2001 until 2008. Prior to joining ev3, Inc., Mr. Schaubach was a Director of Business Systems Integration at Medtronic plc, from 2000 until 2001, and a Director of Information Services in the SCIMED Division at Boston Scientific Corporation from 1994 until 2000. Mr. Schaubach holds a B.A. in Computer Science from the University of North Texas.

About Tactile Medical

Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical’s Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company’s unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

Legal Notice Regarding Forward-Looking Statements:

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “confident,” “outlook” or “project” or the negative of these words or other variations on these words or comparable terminology.  The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

CONTACT: Investor Inquiries:

Mike Piccinino, CFA
Managing Director
Westwicke Partners

Contact Data